Abstract
The emergence of HIV and AIDS is narrated here through the eyes of the legendary Irish traveller Gulliver, observing the replication, cross-species origin, evolution, diversity and transmission of HIV. Ethical problems of vaccine trials, the social impact of AIDS, and prospects for its prevention, including the development of topical virucidal lotions, are discussed. The existence of a growing proportion of HIV-infected, immunocompromised children and adults may significantly affect current immunization programmes and the evolution of opportunistic infections.
Similar content being viewed by others
Main
See Box 1
How HIV commandeers host cells
Like all viruses, HIV is a parasite that replicates within living cells of the host (Fig. 1). HIV has nine genes and belongs to the lentivirus genus of retroviruses. It carries two RNA copies of its genome within virus particles. Viral reverse transcriptase converts them to one DNA copy within the infected cell (a form of meiosis involving genome recombination), which enables HIV to be integrated into the host DNA and to use the cell's genetic machinery to make new virus. Reverse transcriptase was the first target of antiviral drugs in clinical use5, the second being the protease enzyme that cleaves precursor proteins into components of the viral core during particle assembly. Other promising targets for anti-HIV drug development include the interaction with cell-surface receptors and integration of the viral DNA into host chromosomal DNA.
HIV infects cells mainly of the immune system8. T-helper lymphocytes express the CD4 antigen to which HIV attaches. Chemokine receptors serve as co-receptors that guide the viral envelope glycoproteins into a conformation permitting membrane fusion and entry into the cell. Although many co-receptors have been defined in culture, only CCR5 and CXCR4 seem to be used in vivo, by HIV strains having an 'R5' or an 'X4' tropism, respectively10. Besides CD4+ lymphocytes, macrophages and dendritic cells also harbour HIV. Macrophages are an important reservoir of infection, including the microglia in the brain7. Dendritic cells bind HIV through DC-SIGN receptors and carry it from mucosal ports of entry to the lymph nodes where they activate lymphocyte infection11. High levels of virus replication and cell destruction and turnover occur at all stages of infection3,5, although it takes years before the CD4+ cell count falls below the threshold for symptomatic immunodeficiency to become manifest.
See Box 2
Adaptation and spread
The cross-species transfer of HIV-1 and HIV-2 from chimpanzees and mangabeys into humans resulted in a change of virulence, as the natural simian hosts do not develop AIDS. Yet the pathogenesis of primate immunodeficiency viruses seem oddly uncoupled from their transmission dynamics. For example, asymptomatic sooty mangabeys carry viral loads as high as the macaques and humans that succumb to AIDS from infection by essentially the same virus15. This change of virulence may therefore be determined more by the host response to infection than by properties of the virus. One possible explanation is that HIV infection activates the human immune system, providing a larger pool of cells permissive for ongoing infection and for apoptosis (programmed cell death)16. The eventual depletion of CD4+ T-lymphocytes3 finally tips the balance of power between virus and the immune system in favour of the virus. If we understood better how the host controls SIV infection in mangabeys and chimpanzees, we might find ways to effect HIV control in humans.
HIV-2 seems to be less pathogenic than HIV-1 and to cause disease more slowly17. But this observation may mask a bimodal spectrum of virulence in which some individuals carrying HIV-2 progress to AIDS at a similar rate to those with HIV-1, whereas a higher proportion are long-term non-progressors. It is also noteworthy that among the HIV-2-infected people who do develop AIDS, brain disease is more common18.
HIV-1 and -2 probably encountered many hurdles in adapting to their new host. Some expeditions to humankind may have petered out altogether; others like HIV-1 group N and O remained geographically close to the point of cross-species transfer. But HIV-1 group M was more adventurous, taking every opportunity to transmit its progeny by exploring the highways and intimate byways of its host's behaviour — crossing sexually from man to woman, woman to man and man to man, crossing vertically from mother to child, and horizontally through hollow needles.
HIV diversity
Needles especially may have unwittingly aided the early dispersion of HIV, owing to the widespread re-using of needles and syringes in Africa in the mid-twentieth century19. Once HIV became established in its new host, overland trucks, overseas troops and airlines enabled a far more rapid and widespread dispersion than mosquitoes could have effected. HIV-1 group M diversified into distinct subtypes or clades, A–H, with subtype B colonizing the Americas, subtype C moving south to the Cape and north to the Horn of Africa, and subtype E east to Thailand. This outward radiation of HIV-1 group M genomes can be plotted as a starburst20, but when the clades crossed paths, HIV-1 recombined, so that some genomes have a highly complex genealogy21,22. Even recombinants between groups M and O have been recorded23,24.
See Box 3
Is HIV evolving in the sense of changing its phenotype, mode of replication, virulence and transmission22,26? Or, is it merely expanding, with genetic diversity representing more noise than biological signal? The answer is both, for the basic molecular biology of replication remains constant (Fig.1) while the explosion of HIV into the new terrain of the human body and the human population has allowed an unprecedented degree of genetic diversity, upon which natural selection can then play. HIV selection occurs rapidly in response to antiretroviral drugs5 and immune attack4, compounding the problem of vaccine development6. It occurs when the virus adapts to use new co-receptors for entry to the host cell, but an identical mutation can both alter cell tropism and lead to escape from neutralization27. So it is a moot point as to which is exerting the selective pressure.
There is much we do not yet understand about HIV variation. Is there selection of variants for different compartments such as the lymph nodes and brain, or do the differences reflect stochastic founder effects? Do the envelope variants that emerge in late-stage infection, with a tendency to switch from R5 to X4 phenotype, really exacerbate progression to AIDS, or are they opportunistic variants that cannot emerge until CD4 T-cell counts fall below a threshold level? Why have X4 viruses not emerged in subtype C28? Why is the R5 phenotype usually reset at transmission? One explanation is that only R5 viruses can bind to or infect dendritic cells such as Langerhans cells in the mucosa11, yet R5 viruses are also selected following parenteral transmission. Are some subtypes more virulent than others? Could HIV-1 eventually become attenuated22?
HIV is an ideal organism for functional genomics modelling; HIV is a ready-made experiment in maximal mutagenesis while maintaining function and replicative fitness. This has already been exemplified for HIV-1 reverse transcriptase and protease, for which there exist crystal structures, resistant variants to numerous drugs, a vast sequence database and relative fitness data. The degree of genomic diversity that HIV generates in a single infected individual can be greater than the worldwide diversity of influenza A virus during an epidemic29. Where, then, can HIV take us, with millions of infected people each possessing such viral diversity?
How conservative is the HIV phenotype and what new tricks might HIV learn? One nightmare scenario for us would be if HIV were to change its mode of transmission. If Yersinia pestis can switch from flea-borne bubonic plague to the air-borne pulmonary form of the disease, could HIV also sample new transmission dynamics — adding saliva, aerosol or arthropod vectors to the sex and blood it already enjoys? Forget the mosquitoes beloved of yellow fever, but consider ticks and biting bugs. Can we be sure that it is beyond the ingenuity of HIV to travel aboard the mouthparts (analogous to dirty needles) during interrupted feeding of common bugs such as the cone-nosed Rhodnius in Brazil, or the bed-bug Cimex in Russia? After all, horseflies or clegs transmit the lentivirus, causing equine infectious anaemia30. Identifying a new route of transmission may be overlooked unless surveillance methods are designed to detect it. Sentinel cases might be children with HIV-negative parents.
Prevention and intervention
Uneven as the landscape is, HIVland looks set to extend its borders to grasp tens of millions more infected people31. There are, however, some means of slowing its expansion, and some badly affected communities have managed to reduce the rate of HIV transmission through health education2. Restraint on the number of sexual partners, treatment of common sexually transmitted infections (which increase susceptibility to HIV) with antibiotics and antivirals, promoting condom use, and clean needle-exchange programmes all help to curb HIV transmission.
The identification of protective factors of HIV transmission does not necessarily make prevention easy. For instance, it is now clear that circumcised men in Africa have a significantly lower probability of acquiring HIV infection32. These epidemiological findings make biological sense, given the high density of Langerhans cells in the prepuce33. Although some communities that did not previously practise circumcision are beginning to do so, promulgating such an intervention as public-health policy is fraught with problems. Not only is circumcision a sensitive cultural issue, but a false sense of security might be counterproductive. Although circumcision reduces the chances of HIV infection in men by approximately 60%, it might lead to a rise in HIV transmission through higher-risk sex if men considered themselves to be completely protected. Condoms would be more effective if only men everywhere could be persuaded to adopt them, and to adhere to their use regularly34.
The Cinderella of HIV research is the development of topical microbicides or virucides. Compared with the research funding available to her big sisters, antiretroviral drugs and vaccines, virucides need to attract more support for research and development34. If virucides can be incorporated successfully into vaginal gels, foams and suppositories, they would enable women to provide a means to improving sexual health for both sexes. Whereas the spermicide nonoxynol-9 is too inflammatory, certain sulphated polysaccharides show promise for formulation as anti-HIV molecules for topical application35. Virucides could be our best hope for preventing HIV infection until we can deliver a safe, efficacious, affordable vaccine.
Although HIV elicits strong immune responses, these ultimately fail to control infection4. Nabel6 catalogues the obstacles confronting an effective HIV vaccine, while pointing to some promising leads. Cohen36 has documented the lack of coordination of HIV vaccine research and development. Even a vaccine with <50% efficacy could have a significant impact in reducing HIV transmission37. Yet a dilemma exists between purists who wish to see scientific proof of efficacy, and pragmatists who believe that the evidence will come only from conducting human trials36.
The pressure to conduct clinical trials of candidate vaccines is intense. An immunogen based on the gp120 envelope antigen has progressed to phase III clinical trials, after approval by international and local ethical committees, despite no evidence of efficacy, on the lilliputian logic that if it is available it must be used. Gp120 stimulates a humoral response, including weak neutralization of the HIV strain from which it is derived. This type of vaccine might conceivably be worse than useless, as it might elicit antibodies that enhance infection by targeting macrophages and dendritic cells via complement and Fc receptors8. The trial design is unlikely to reveal any increased risk because the enhancement may occur after the period of follow-up among high-risk vaccinees has ended (Fig. 2); and by targeting people illicitly injecting drugs there is likely to be significant loss to follow-up by those at greatest risk. When this writer ventured to raise these points at an AIDS vaccine conference last May, he was politely but firmly rebuked by an envoy from one of the worst afflicted countries in Asia on the grounds that 'something must be done' for his people, a view that won overwhelming applause from the participants. One remains concerned that the heart overrules the head, although we earnestly hope that these fears will prove to be unfounded.
To most readers of Nature, AIDS research has followed a steady progress of science successfully translated into medical practice. AIDS was first noted9 in 1981. Within two years HIV was identified, and by late 1985, serological screening was in place to prevent further infection through blood transfusion and blood products. By 1986, the first antiretroviral drug, zidovudine, was in clinical trial, culminating in the success of combination chemotherapy5 based on rational drug design, which has led to a 60% reduction of AIDS mortality in the United States (Fig. 3). Our knowledge of HIV and of cell biology is immense, although vaccine development has been much slower than forecast.
Among the people most affected by HIV, Western gay men seized the opportunity to convert stigma and fear into empowerment to set the agenda for research and public health, often knowing more about their condition than their doctors. But for the 90% of HIV-infected people in developing countries there has been little or no access to these scientific advances. There is currently a North–South dispute between protecting the patents of the pharmaceutical companies and demanding access to cheaper generic drugs as a human right. But even generic drugs are beyond the health budgets of the worst affected nations. Besides, if 20% of the US population were HIV-infected, its health management and insurance systems would collapse.
Culture and belief in HIVland
Sometimes the drugs are shunned even when offered at no cost. After HIV swept across southern Africa in the 1990s, some leaders blamed poverty rather than HIV for AIDS, finding scapegoats to attack, just as when the Black Death came to Europe in 134738,39. One leant his ear to siren voices singing that HIV was harmless and that AIDS was not transmissible, so encouraging the misconception that AIDS in Africa is a distinct disease, contrary to all the evidence40,41.
HIV will not drive humans to extinction, for even rabbits survived the 99% mortality of myxomatosis. But HIV has already reduced life expectancy2 and will destabilize society by selectively removing its young adults.
See Box 4
Effect of HIV on infectious disease
The impact of HIV/AIDS on other infectious diseases will be enormous. First, opportunistic infections, which seldom cause serious disease in immunocompetent people, are frequently the sentinels of AIDS9. Over 100 opportunistic infections by viruses, bacteria, fungi and protozoa have been associated with AIDS. Disease by known pathogens such as tuberculosis also becomes exacerbated in AIDS. Antibiotic resistance to bacteria is more frequently found, and HIV-infected adults may regain susceptibility to childhood infections such as Streptococcus pneumoniae46. Thus the HIV-infected population can spread virulent strains of pathogens such as tuberculosis to others who are not necessarily at risk of HIV itself.
Second, HIV infection affects public-health immunization programmes. For instance, multivalent pneumococcal vaccine is ineffective in HIV-infected Africans47. Live 'attenuated' vaccines such as vaccinia, measles and oral polioviruses may become dangerous pathogens in the immunosuppressed person48,49,50. Moreover, HIV can convert acute infections into long-persistent ones50, as cell-mediated immune responses are crucial for clearance of virus infections like enteroviruses, measles, mumps and influenza. The World Health Organization needs to give further thought to the power of HIV to scupper its disease-eradication programmes49. With 1.5 million HIV-infected children in Africa, can we really eradicate polio within the next few years?
Third, AIDS could conceivably generate new types of epidemics. When the proportion of immunodeficient individuals in a population remains very low, the chance of direct transmission of opportunistic infections from one to another is even smaller. But HIV-infected people can act as incubators of microbes that previously relied on animal reservoirs: for example, the Mycobacterium avium complex, canine Toxoplasma, alphaviruses of birds, enteric infections of farm animals, and numerous other microbes not normally transmissible between humans.
With the AIDS pandemic, such microbes now have a new host population in which to play darwinian selection. Where 10% or more of a community are HIV-infected, direct transmission between immunodeficient individuals becomes plausible. Microbes that are poorly adapted for human infection could become well adjusted, first to the immunodeficient host and eventually to immunocompetent humans, provided they learn the tricks of human-to-human transmission. These could include free-living microbes from the environment51,52, including non-tuberculous Mycobacteria, Legionnella, Pseudomonas, Fusarium and other fungi, as well as microbes and parasites from animal sources.
Free-living bacteria, fungi and protozoa now have 37 million and rising immunocompromised people in which to learn to become human parasites. The bacteria could acquire antibiotic resistance or adaptive, pathogenic genes from the plasmids, phages and mobile pathogenicity islands53 of their human-adapted relatives, and yet escape the vaccines now in use. Moreover, animal infections could gain a firm foothold in the human population, particularly fast-evolving RNA viruses. The vast number of susceptible humans is a novel, unique window of opportunity for microbes originating from animals, the soil or water to evolve into human pathogens. This issue of the potential community impact of a massive immunodeficient reservoir therefore demands analysis by those who model infectious disease dynamics and evolution. Long after HIV itself is controlled (we hope) by immunization, new diseases may roam former HIVland.
References
Swift, J. Gulliver's Travels (Penguin, London, 1967). [First published by B. Motte, London, 1726.]
Piot, P., Bartos, M., Ghys, P. D., Walker, N. & Schwartländer, B. The global impact of HIV/AIDS. Nature 410, 968–973 (2001).
McCune, J. M. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 410, 974–979 (2001).
McMichael, A. J. & Rowland-Jones, S. L. Cellular immune responses to HIV. Nature 410, 980–987 (2001).
Richman, D. D. HIV chemotherapy. Nature 410, 995–1001 (2001).
Nabel, G. J. Challenges and opportunities for development of an AIDS vaccine. Nature 410, 1002–1007 (2001).
Kaul, M., Garden, G. A. & Lipton, S. A. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410, 988–994 (2001).
Levy, J. A. HIV and the Pathogenesis of AIDS (American Society for Microbiology, Washington DC, 1998).
Centers for Disease Control & Prevention. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men in New York City and California. Mort. Morb. Wkly. Rep. 30, 305–308 (1981).
O'Brien, S. J. & Moore, J. P. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol. Rev. 177, 99–111 (2000).
Geijtenbeek, T. B. et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100, 587–597 (2000).
Wain-Hobson, S. & Weiss, R. A. (eds) The Origins of HIV and the AIDS Epidemic (Phil. Trans. R. Soc. Lond. B 356) (The Royal Society, London, 2001).
Blancou, P. et al. Polio vaccine samples not linked to AIDS. Nature (in the press).
Berry, N. et al. Analysis of oral polio vaccine CHAT stocks. Nature (in the press).
Kurth, R. & Norley, S. Why don't the natural hosts of SIV develop simian AIDS? J. NIH Res. 8, 33–37 (1996).
Dalgleish, A. G. et al. The role of HIV gp120 in the disruption of the immune system. Immunol. Lett. 66, 81–87 (1999).
Whittle, H. et al. HIV-2-infected patients survive longer than HIV-1-infected patients. AIDS 8, 1617–1620 (1994).
Lucas, S. B. et al. The mortality and pathology of HIV infection in a west African city. AIDS 7, 1569–1579 (1993).
Marx, P. A., Alcabes, P. G. & Drucker, E. Serial human passage of SIV unsterile injecting and the emergence of epidemic HIV in Africa. Phil. Trans. R. Soc. Lond. B 356 (in the press).
Korber, B. et al. Timing the ancestor of the HIV-1 pandemic strains. Science 288, 1789–1796 (2000).
Vidal, N., Mulanga-Kabeya, C., Nzilambi, N., Delaporte, E. & Peeters, M. Identification of a complex env subtype E HIV type 1 virus from the Democratic Republic of Congo, recombinant with A, G, H, J, K, and unknown subtypes. AIDS Res. Hum. Retroviruses 16, 2059–2064 (2000).
Malim, M. H. & Emerman, M. HIV-1 sequence variation, drift, shift, and attenuation. Cell 104, 469–472 (2001).
Takehisa, J. et al. Human immunodeficiency virus type 1 intergroup (M/O) recombination in Cameroon. J. Virol. 73, 6810–6820 (1999).
Peeters, M. et al. Characterization of a highly replicative intergroup M/O human immunodeficiency virus type 1 recombinant isolated from a Cameroonian patient. J Virol 73, 7368–7675 (1999).
Hamilton, W. D. Narrow Roads of Gene Land: Evolution of Social Behaviour (Freeman, Oxford, 1995).
Sala, M. & Wain-Hobson, S. Are RNA viruses adapting or merely changing? J. Mol. Evol. 51, 12–20 (2000).
McKnight, A. et al. Change in tropism upon immune escape by human immunodeficiency virus. J. Virol. 69, 3167–3170 (1995).
Ping, L. H. et al. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J. Virol. 73, 6271–6281 (1999).
Korber, B. et al. in The Changing face of HIV and AIDS (eds Weiss, R. A., Adler, M. W. & Rowland-Jones, S. L.) (Br. Med. Bull., in the press).
Montelaro, R. C., Ball, J. M. & Rushlow, K. E. in The Retroviridae (ed. Levy, J. A.) 257–360 (Plenum, New York, 1993).
Carael, M., Buvé, A. & Awusabo-Asare, K. The making of HIV epidemics: what are the driving forces? AIDS 11, S23–S31 (1997).
Weiss, H. A., Quigley, M. A. & Hayes, R. J. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 14, 2361–2370 (2000).
Szabo, R. & Short, R. V. How does male circumcision protect against HIV infection? Br. Med. J. 320, 1592–1594 (2000).
Hill, R., Ryan, J., Stone, A. & Fransen, L. Vaginal microbicides for the prevention of HIV/AIDS: assessment of the potential market. Int. J. Pharm. 14, 271–278 (2000).
McCormack, S., Hayes, R., Lacey, C. J. & Johnson, A. M. Microbicides in HIV prevention. Br. Med. J. 322, 410–413 (2001).
Cohen, J. Shots in the Dark: The Wayward Search for an HIV Vaccine (Norton, New York, 2001).
Anderson, R. M. & Garnett, G. P. Low-efficacy HIV vaccines: potential for community-based intervention programmes. Lancet 348, 1010–1013 (1996).
Lederberg, J. Infectious history. Science 288, 287–293 (2000).
Ziegler, P. The Black Death (Penguin, London, 1970).
Durban Declaration. Nature 406, 15–16 (2000).
Morgan, D. & Whitworth, J. A. The natural history of HIV-1 infection in Africa. Nature Med. 7, 143–145 (2001).
Ranger, T. & Slack, P. (eds) Epidemics and Ideas: The Historical Perception of Pestilence (Cambridge Univ. Press, 1992).
Quétel, C. History of Syphilis (Blackwell, Oxford, 1990).
Bynum, W. F. Sexually transmitted retribution. Nature 407, 943 (2000).
Shilts, R. And the Band Played On—Politics, People and the AIDS Epidemic (St Martin's, New York, 1987).
Crewe-Brown, H. H. Streptococcus pneumoniae blood culture isolates from patients with and without HIV infection: alterations in penicillin susceptibilities and in serogroups or serotypes. Clin. Inf. Dis. 25, 1165–1172 (1997).
French, N. et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 355, 2106–2111 (2000).
Chitsike, I. & van Furth, R. Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in a child with HIV infection in Zimbabwe. Brit. Med. J. 318, 841–843 (1999).
Wood, D. J., Sutter, R. W. & Dowdle, W. R. Stopping poliovirus vaccination after eradication: issues and challenges. Bull. World. Health Organ. 78, 347–357 (2000).
Moss, W. J., Cutts, F. & Griffin, D. E. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin. Infect. Dis. 29, 106–112 (1999).
Shafer, R. W. & Sierra, M. F. Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and other nontuberculous mycobacteria in an area of endemicity for AIDS. Clin .Infect. Dis. 15, 161–162 (1992).
Mendelson, M. Fungal infections in the immunocompromised. Microbiol. Today 28, 10–12 (2001).
Hacker, J. & Kaper, J. B. Pathogenicity islands and the evolution of microbes. Ann. Rev. Microbiol. 54, 641–679 (2000).
Acknowledgements
The scribbler is indebted to V. Gant, P. Hale, A. McKnight, R. S. Tedder and S. Wain-Hobson for sceptical discussions. His AIDS research is supported by the Medical Research Council.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weiss, R. Gulliver's travels in HIVland. Nature 410, 963–967 (2001). https://doi.org/10.1038/35073632
Issue Date:
DOI: https://doi.org/10.1038/35073632
This article is cited by
-
Antimicrobial potential of 27 plants consumed by chimpanzees (Pan troglodytes verus Blumenbach) in Ivory Coast
BMC Complementary and Alternative Medicine (2015)
-
Protein intrinsic disorder as a flexible armor and a weapon of HIV-1
Cellular and Molecular Life Sciences (2012)
-
Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis
Science China Life Sciences (2010)
-
Social and environmental risk factors in the emergence of infectious diseases
Nature Medicine (2004)
-
HIV and AIDS: looking ahead
Nature Medicine (2003)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.